Diagnostics News and Research

RSS

Investigation of IDH1 gene mutations in brain cancer receives new funds

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2’s funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios’s ongoing research into the development of new IDH1 therapeutics and diagnostics.

21 Dec 2009

Autism spectrum disorder dramatically increasing, early intervention crucial

In the wake of today's new report from the U.S. Centers for Disease Control (CDC) stating that autism now affects 1% or 1 in every 110 American children, Autism Speaks, North America's largest autism science and advocacy organization, called on the U.S. government to immediately step up its efforts - and dramatically increase funding - to address the growing global autism public health crisis.

19 Dec 2009

Second wave of H1N1 virus infection in the U.S. comes to an end

Rates of 2009 H1N1 influenza virus testing in the U.S. have declined more than 75 percent since their peak in late October, suggesting that the "second wave" of virus infection that sickened tens of millions of Americans since it began four months ago may be coming to an end, according to a new report by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services.

19 Dec 2009

CLIAWAIVED.COM expands its business into GPO market by signing the first major GPO

CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.

19 Dec 2009

InHealth to further understand socioeconomic impact of medical devices and diagnostics

As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.

19 Dec 2009

BARDA awards $400M for developing tests and devices to determine radiation absorption after a nuclear/radiological incident

The HHS Biomedical Advanced Research and Development Authority (BARDA) is awarding nine contracts for the advanced research and development of more effective tests and devices to determine the level of radiation a person has absorbed after a nuclear or radiological incident. The contracts total $35 million for the initial phase and up to $400 million over five years.

19 Dec 2009

Leerink Swann announces availability of its 2010 healthcare investment outlook report

Leerink Swann, the leading healthcare-focused investment banking firm, today announced the availability of the firm’s 2010 healthcare investment outlook report.

18 Dec 2009

Danaher offers GBP 50 million pounds for Genetix Group acquisition

Danaher Corporation announced today its intention to make a recommended cash takeover offer, through an indirect wholly owned subsidiary, to acquire all of the issued and to be issued shares of Genetix Group plc for 85 pence per share implying an aggregate price of approximately GBP 50 million pounds (USD $82 million) net of cash acquired.

From Danaher 18 Dec 2009

Rosetta Genomics announces third-quarter 2009 financial results

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2009 and provided a business update.

18 Dec 2009

ANIS2's second edition on ‘micro and nanotechnologies for cancer research’ is open for registrations

There is still time until January 8 2010 to register for the second edition of the Alp NanoBio International School (ANIS2), which will be held in Sterzing/Vipiteno (Bozen, Italy) from 11 to 15 of January 2010, organized by the Centre of Excellence LATEMAR - funded by MIUR, in collaboration with the Fondazione Bruno Kessler (FBK).

18 Dec 2009

Biovator and BASF sign collaboration agreement to develop In Vitro test systems

The Sweden-based biotech company Biovator and the global chemical industry leader BASF have signed a collaboration agreement for final development of In Vitro test systems capable of identifying the potential of chemical compounds to induce allergic reaction in humans. The agreement also includes a five-year BASF option of final product deliveries.

18 Dec 2009

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Advanced Medical Diagnostics SA, a privately held company committed to providing innovative computer-aided solutions (HistoScanning™) that improve the diagnostic interpretation of ultrasound scans, today announced a collaboration with the BUND-DER-UROLOGEN for the opening of 15 Tissue Differentiation Diagnostic Centres.

18 Dec 2009

2010 Dr. Paul Janssen Award for Biomedical Research open for nomination

The Dr. Paul Janssen Award for Biomedical Research has opened the 2010 call for nominations. The $100,000 Award recognizes individuals whose efforts have made significant transformational contributions towards the improvement of human health. Nomination forms are available at pauljanssenaward.com and will be accepted until February 15, 2010.

18 Dec 2009

BioMS Medical invests in Spectral Diagnostics to advance treatment for sepsis

Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.

18 Dec 2009

Practice Fusion continues to be the fastest growing EHR community in the US

Practice Fusion today announced that the company's user base has grown 400% in 2009 to surpass 25,000 medical professionals. Practice Fusion continues to be the fastest growing Electronic Health Record (EHR) community in the US, serving the needs of family practice and private practice physicians across the country.

18 Dec 2009

Roche Diagnostics and Takara Bio enter into license agreement

Roche Diagnostics and Takara Bio, the Shiga (Japan)-based supplier of systems for use in life science research, announced that they have entered into a license agreement for use of the melting curve analysis technology and SYBR Green techniques in their Kits and Instruments for Real Time PCR.

From Roche Sequencing and Life Science 18 Dec 2009

FDA clears Agendia's MammaPrint breast cancer recurrence test for all ages

Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians.

17 Dec 2009

Full Accreditation in Health Utilization Management awarded to DNA Direct

DNA Direct, a leading provider of guidance and decision support for genomic medicine, announced today that it has been awarded Full Accreditation in Health Utilization Management by URAC, a Washington D.C.-based health care accrediting organization that establishes quality standards for the health care industry.

17 Dec 2009

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

John Howell, CEO of Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today formally commented on the anticipated timeline for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic Ovarian Cancer Blood Test, which is currently advancing through late-stage development - the rights to which have been assigned exclusively to the Company by Arrayit Corporation.

17 Dec 2009

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Applied Biosystems, part of Life Technologies Corporation, today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking.

17 Dec 2009

Diagnostics News and Research

Investigation of IDH1 gene mutations in brain cancer receives new funds

Autism spectrum disorder dramatically increasing, early intervention crucial

Second wave of H1N1 virus infection in the U.S. comes to an end

CLIAWAIVED.COM expands its business into GPO market by signing the first major GPO

InHealth to further understand socioeconomic impact of medical devices and diagnostics

BARDA awards $400M for developing tests and devices to determine radiation absorption after a nuclear/radiological incident

Leerink Swann announces availability of its 2010 healthcare investment outlook report

Danaher offers GBP 50 million pounds for Genetix Group acquisition

Rosetta Genomics announces third-quarter 2009 financial results

ANIS2's second edition on ‘micro and nanotechnologies for cancer research’ is open for registrations

Biovator and BASF sign collaboration agreement to develop In Vitro test systems

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

2010 Dr. Paul Janssen Award for Biomedical Research open for nomination

BioMS Medical invests in Spectral Diagnostics to advance treatment for sepsis

Practice Fusion continues to be the fastest growing EHR community in the US

Roche Diagnostics and Takara Bio enter into license agreement

FDA clears Agendia's MammaPrint breast cancer recurrence test for all ages

Full Accreditation in Health Utilization Management awarded to DNA Direct

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News